R&D / Publications
Below is a selection of scientific publications that are the product of HRA Pharma-sponsored research activities.
| A prospective study of the provision of emergency contraception in French family planning centers Gainer E, Prudhomme M, Perriot Y, Leroux MC, Bouyer J.Gynecol Obstet Fertil. 2005 Jun;33(6):403-8. |
| An inactivating mutation within the first extracellular loop of the thyrotropin receptor impedes normal posttranslational maturation of the extracellular domain. Sura-Trueba S, Aumas C, Carre A, Durif S, Leger J, Polak M, de Roux N.Endocrinology. 2009 Feb;150(2):1043-50. |
| Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, Sweden and Portugal. Gainer E, Blum J, Toverud EL, Portugal N, Tyden T, Nesheim BI, Larsson M, Vilar D, Nymoen P, Aneblom G, Lutwick A, Winikoff B.Contraception. 2003 Aug;68(2):117-24. |
| Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED.Contraception. 2007;75(6 Suppl):S99-103. |
| Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. J Clin Endocrinol Metab. 2007;92(9):3582-9. |
| Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Hum Reprod. 2010 Jul 15. [Epub ahead of print] |
| Is it worth paying more for emergency hormonal contraception? The costeffectiveness of ulipristal acetate versus levonorgestrel 1.5 mg. Thomas C M, Schmid R, Cameron S J Fam Plann Reprod Health Care 2009; 36(4): 197–201. |
| Levonorgestrel-only emergency contraception: real-world tolerance and efficacy. Gainer E, Méry C, Ulmann A.Contraception. 2001 Jul;64(1):17-21. |
| Levonorgestrel pharmacokinetics in plasma and milk of lactating women who take 1.5 mg for emergency contraception. Gainer E, Massai R, Lillo S, Reyes V, Forcelledo ML, Caviedes R, Villarroel C, Bouyer J.Hum Reprod. 2007 Jun;22(6):1578-84. |
| Linkage and mutational analysis of familial thyroid dysgenesis demonstrate genetic heterogeneity implicating novel genes. Castanet M, Sura-Trueba S, Chauty A, Carré A, de Roux N, Heath S, Léger J, Lyonnet S, Czernichow P, Polak M.Eur J Hum Genet. 2005 Feb;13(2):232-9. |
| M909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins Isabelle Petit-Topin, Nathalie Turque, Jérôme Fagart, André Ulmann, Erin Gainer and Marie-Edith Rafestin-OblinMol Pharmacol. Mol Pharmacol. 2009 Jun;75(6):1317-24. Epub 2009 Mar 16. |
| Menstrual bleeding patterns following levonorgestrel emergency contraception. Gainer E, Kenfack B, Mboudou E, Doh AS, Bouyer J.Contraception. 2006 Aug;74(2):118-24. |
| Misoprostol: Why Gymiso? Ulmann A.Gynecol Obstet Fertil. 2006 Oct;34(10):883-4. |
| Molecular mechanisms of thyroid dysgenesis. Polak M, Sura-Trueba S, Chauty A, Szinnai G, Carré A, Castanet M.Horm Res. 2004;62 Suppl 3:14-21. Review. |
| Pharmacologic properties of CDB(VA)-2914. Gainer EE, Ulmann A.Steroids. 2003 Nov;68(10-13):1005-11. |
| Pharmacy access to emergency contraception in Europe. Ulmann A, Gainer E.Perspect Sex Reprod Health. 2002 Sep-Oct;34(5):271; |
| Polymorphic length of FOXE1 alanine stretch: evidence for genetic susceptibility to thyroid dysgenesis. Carré A, Castanet M, Sura-Trueba S, Szinnai G, Van Vliet G, Trochet D, Amiel J, Léger J, Czernichow P, Scotet V, Polak M. Hum Genet. 2007 Dec;122(5):467-76. |
| Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T. Hum Reprod. 2006;21(9):2408-16. |
| Progestogen-only emergency contraception. Gainer E, Méry C, Ulmann A.J Fam Plann Reprod Health Care. 2003 Apr;29(2):60. |
| Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. Szinnai G, Lacroix L, Carré A, Guimiot F, Talbot M, Martinovic J, Delezoide, AL, Vekemans M, Michiels S, Caillou B, Schlumberger M, Bidart JM, Polak M.J Clin Endocrinol Metab. 2007 Jan;92(1):70-6. |
| Surfing on the morning after: analysis of an emergency contraception website. Gainer E, Sollet C, Ulmann M, Lévy D, Ulmann A.Contraception. 2003 Mar;67(3):195-9. |
| The development of mifepristone: a pharmaceutical drama in three acts. Ulmann A.J Am Med Womens Assoc. 2000;55(3 Suppl):117-20. |
| The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval. Tremblay D, Gainer E, Ulmann A.Contraception. 2001 Dec;64(6):327-31. |
| Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Obstetrics & Gynecology. 115(2, Part 1):257-263, February 2010 |
| Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis Glasier A, Cameron S, Fine P, Logan S, Casale W, Van Horn J, Sogor L, Blithe D, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Lancet. 2010 Feb 13;375(9714):555-62 |